Which laboratory tests should a nephrologist obtain to monitor chronic kidney disease (CKD)?

Laboratory Monitoring for Chronic Kidney Disease by Nephrologists

Nephrologists should monitor CKD patients with serum creatinine/eGFR and urine albumin-to-creatinine ratio (UACR) at minimum annually for low-risk patients, with more frequent testing (2-4 times yearly) for higher-risk individuals, plus electrolytes (especially potassium), complete metabolic panel, hemoglobin, calcium, phosphate, intact PTH, and 25-hydroxyvitamin D based on CKD stage. 1, 2

Core Monitoring Tests (All CKD Patients)

Kidney Function Assessment

• Serum creatinine with eGFR calculation using the CKD-EPI 2021 equation (race-free) should be measured at every monitoring visit 1, 2
• Urine albumin-to-creatinine ratio (UACR) on random spot urine samples provides independent prognostic information beyond eGFR for cardiovascular events, CKD progression, and mortality 1, 2
• An eGFR decline >20% on subsequent testing exceeds expected variability and warrants immediate evaluation 1
• Among patients initiating hemodynamically active therapies (ACE-I/ARB/SGLT2i), eGFR reductions >30% exceed expected variability and require assessment 1
• A doubling of UACR on subsequent testing exceeds laboratory variability and demands evaluation 1

Electrolyte and Metabolic Panel

• Complete metabolic panel including sodium, potassium, chloride, bicarbonate, BUN, and creatinine should be obtained to screen for metabolic acidosis, hyperkalemia, and other electrolyte abnormalities 2
• Potassium monitoring is critical, especially in patients on RAS inhibitors or mineralocorticoid receptor antagonists, with rechecking within 2-4 weeks after medication initiation 2
• Potassium should be monitored at 1 month after starting nonsteroidal MRAs, then every 4 months thereafter 2

Stage-Specific Monitoring (CKD G3-G5)

Mineral-Bone Disorder Screening

• Intact parathyroid hormone (PTH) should be measured in CKD stage 3 and beyond, as PTH begins rising when eGFR falls below 60 mL/min/1.73 m² 2
• Serum calcium and phosphate levels require monitoring to detect mineral-bone disorder complications 2
• 25-hydroxyvitamin D should be assessed, as deficiency is common and contributes to secondary hyperparathyroidism 2

Anemia Evaluation

• Hemoglobin measurement is essential for detecting CKD-associated anemia, which becomes increasingly prevalent as kidney function declines 2, 3
• When anemia is identified, comprehensive evaluation should include iron studies, vitamin B12, and folate to identify additional causes beyond erythropoietin insufficiency 3, 4

Monitoring Frequency Based on Risk Stratification

Annual Monitoring (Low Risk)

• CKD G1-G2 with UACR <30 mg/g (A1 category) requires annual assessment of eGFR and UACR 1, 2

Semi-Annual Monitoring (Moderate Risk)

• CKD G3a with UACR 30-300 mg/g or CKD G3b with UACR <30 mg/g warrants monitoring 2 times per year 2

Quarterly Monitoring (High Risk)

• CKD G3b-G4 with UACR 30-300 mg/g or any stage with UACR >300 mg/g requires monitoring 3-4 times per year 1, 2
• Patients at higher risk of progression should be assessed more frequently when measurements will impact therapeutic decisions 1

Additional Laboratory Tests for Specific Indications

Cardiovascular Risk Assessment

• HbA1c should be measured in diabetic patients to guide glucose control and assess cardiovascular risk 2
• Lipid panel is indicated for cardiovascular risk stratification, as CKD patients have 5-10 times higher cardiovascular mortality risk 2

Etiology Determination (When Unclear)

• Hepatitis B and C serologies when infectious etiology is considered 2
• Autoimmune workup including complement levels (C3, C4), ANA, ANCA, and anti-GBM antibodies to identify glomerulonephritis 2
• Serum and urine protein electrophoresis with immunofixation plus serum free light chains to exclude monoclonal gammopathies 2

Quality Assurance for Laboratory Testing

Analytical Standards

• Creatinine assays must be traceable to isotope dilution mass spectrometry (IDMS) with minimal bias and acceptable imprecision 1, 5
• Laboratories should participate in external quality assessment programs for both urine albumin and creatinine, including ACR calculation 1
• Point-of-care testing devices, when used where laboratory access is limited, must meet the same pre-analytical, analytical, and post-analytical quality criteria as laboratory-based testing 1

Reporting Requirements

• eGFR should be automatically calculated and reported with every creatinine measurement using the regionally appropriate equation 1
• UACR is preferred over 24-hour urine collections for albuminuria assessment 2, 6
• Point-of-care ACR devices should produce positive results in 85% of people with significant albuminuria (ACR ≥30 mg/g) 1

Risk Prediction Tools

Kidney Failure Risk Assessment

• Externally validated risk equations should be used in CKD G3-G5 to estimate absolute risk of kidney failure 1
• A 5-year kidney failure risk of 3-5% can determine need for nephrology referral beyond eGFR or UACR criteria 1
• A 2-year kidney failure risk >10% guides timing of multidisciplinary care 1
• A 2-year kidney failure risk >40% determines timing for modality education and kidney replacement therapy preparation 1

Disease-Specific Equations

• Use disease-specific, externally validated prediction equations in IgA nephropathy and autosomal dominant polycystic kidney disease 1

Critical Pitfalls to Avoid

• Never rely on serum creatinine alone—always calculate eGFR using validated equations 2
• Never skip albuminuria testing—eGFR and UACR provide independent prognostic information 2
• Do not interpret a single abnormal result as chronic disease—confirm persistence over at least 3 months to differentiate CKD from acute kidney injury 2
• Recognize potassium variability—diurnal and seasonal variation exists, with differences between plasma versus serum samples 2
• Do not discontinue ACE-I/ARB for creatinine increases <30% in the absence of volume depletion 2